"TNM" at study entry in phase I trials
Type de document :
Article dans une revue scientifique: Lettre à l'éditeur
PMID :
URL permanente :
Titre :
"TNM" at study entry in phase I trials
Auteur(s) :
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Smis-Papillon, P. [Auteur]
Vanseymortier, M. [Auteur]
Lebellec, L. [Auteur]
Le Deley, M. C. [Auteur]
Mathoulin-Pelissier, S. [Auteur]

METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Smis-Papillon, P. [Auteur]
Vanseymortier, M. [Auteur]
Lebellec, L. [Auteur]
Le Deley, M. C. [Auteur]
Mathoulin-Pelissier, S. [Auteur]
Titre de la revue :
Bulletin du Cancer
Nom court de la revue :
Bull Cancer
Numéro :
108
Pagination :
P. 671-672
Date de publication :
2021-06
ISSN :
1769-6917
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
By nature, early phase clinical trials are hypothesis-generating trials. Nevertheless, some findings coming from such trials could lead to accelerated approvals. We all know two enthusiastic examples: FDA-approval of ...
Lire la suite >By nature, early phase clinical trials are hypothesis-generating trials. Nevertheless, some findings coming from such trials could lead to accelerated approvals. We all know two enthusiastic examples: FDA-approval of crizotinib soon after large phase I trials showing its obvious activity in ALK-rearranged lung adenocarcinoma [1] and FDA-approval of pembrolizumab in microsatellite instability-high solid tumors based on an overview of five early phase trials including 149 patients [2]. This supports precise data collection to better measure the clinical benefit of investigational new drugs.Lire moins >
Lire la suite >By nature, early phase clinical trials are hypothesis-generating trials. Nevertheless, some findings coming from such trials could lead to accelerated approvals. We all know two enthusiastic examples: FDA-approval of crizotinib soon after large phase I trials showing its obvious activity in ALK-rearranged lung adenocarcinoma [1] and FDA-approval of pembrolizumab in microsatellite instability-high solid tumors based on an overview of five early phase trials including 149 patients [2]. This supports precise data collection to better measure the clinical benefit of investigational new drugs.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
CHU Lille
CHU Lille
Date de dépôt :
2023-11-15T06:41:43Z
2024-02-08T12:58:08Z
2024-02-08T12:58:08Z